| abstract |
The present description relates to compounds, compositions and methods for the therapy of hepatitis C infection (HCV). Pharmaceutical compositions containing such compounds and methods for using these compounds in HCV infection therapy are also described. 1. A compound of formula (I) or a pharmaceutically acceptable salt thereof, characterized in that u and u 'are independently 0, 1, 2 or 3; each of D and E is a five-membered aromatic ring containing one, two or three heteroatoms independently selected from nitrogen, oxygen and sulfur; each R1 and R1 'is independently selected from alkoxy, alkoxyalkyl, alkoxycarbonyl, alkyl, arylalkoxycarbonyl, carboxy, formyl, halo, haloalkyl, hydroxy, hydroxyalkyl, NRaRb, (NRaRb) alkyl and (NRaRb) carbonyl; R2 and R2 ', together with the carbon atoms to which they are attached, form a five to eight member ring that optionally contains one or two heteroatoms independently selected from nitrogen, oxygen and sulfur; wherein the five to eight member ring is optionally substituted with one, two or three substituents independently selected from alkoxy, alkoxyalkyl, alkoxycarbonyl, alkyl, alkylsulfonyl, aryl, arylalkyl, arylsulfonyl, carboxy, formyl, halo, haloalkoxy, haloalkyl, hydroxy, hydroxyalkyl, NRaRb, (NRaRb) alkyl, (NRaRb) carbonyl, oxo and spirocycle; each of R3 and R3 'is independently selected from hydrogen, alkoxyalkyl, alkoxycarbonyl, alkoxycarbonylalkyl, alkyl, arylalkoxycarbonyl, carboxy, haloalkyl, heterocyclylalkyl, hydroxyalkyl, (NRaRb) carbonyl and trialkylsilylalkyl alkyl; R4 and R4 'are each independently selected from where; each m is independently 0, 1 or 2; ... |